NCT04935853 is a clinical trial in Biliary Tract Cancer, sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group.

Who is sponsoring NCT04935853?

NCT04935853 is sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group.

What condition does NCT04935853 study?

NCT04935853 studies Biliary Tract Cancer.

Is NCT04935853 still recruiting?

NCT04935853 is currently recruiting now. Last updated 23 July 2025.

Last reviewed 2025-07-23 · How we verify

NCT04935853

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

Recruiting now Last updated 23 July 2025

What this trial tests

trial in Biliary Tract Cancer in 1,350 participants. Currently enrolling.

Timeline

23 May 2022

Primary endpoint
1 June 2030

1 June 2040

Quick facts

Lead sponsor	GERCOR - Multidisciplinary Oncology Cooperative Group
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,350
Start date	23 May 2022
Primary completion	1 June 2030
Estimated completion	1 June 2040
Sites	32 locations across France

Conditions studied

Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Who can join

18 and older, any sex, with Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort.
Adamus N, Edeline J, Henriques J, Fares N, et al · · 2025 · cited 4× · PMID 39897613 · DOI 10.1016/j.jhepr.2024.101279
Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi).
Valery M, Edeline J, Henriques J, Antoun L, et al · · 2025 · PMID 41049585 · DOI 10.1177/17588359251344013

Verify or expand the search:

Other recruiting trials for Biliary Tract Cancer

Currently open trials in the same condition.

NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
NCT06529718 — Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients · Phase 2 · recruiting
NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
NCT07135544 — A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial · Phase 2 · recruiting

Other GERCOR - Multidisciplinary Oncology Cooperative Group trials

Trials by the same sponsor.

NCT05787197 — ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases · recruiting
NCT06059495 — Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study · Phase 2 · recruiting
NCT04894123 — Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients · Phase 2 · terminated
NCT03704480 — Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. · Phase 2 · active not recruiting
NCT03519295 — A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04935853 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GERCOR - Multidisciplinary Oncology Cooperative Group
Last refreshed: 23 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04935853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing